Recombinant Human FLT3LG protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2926

---

Validation Data Gallery

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <1.0 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human FLT3LG protein Thr27-Pro185 (Accession# P49771-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 2323
• Accession: P49771-1
• PredictedSize: 43.6 kDa
• Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

The FMS-related tyrosine kinase 3 (FLT3) ligand (FLT3LG), a growth factor, is mainly derived from lymphocytes in the tumor microenvironment. FLT3LG is predominantly produced by lymphocytes, notably natural killer (NK) cells in mouse and human tumors. It binds to FLT3 on DCs to enhance their differentiation and expansion. Therefore, it may assist DCs in tumor antigen presentation and antitumor immune response. In addition, mature DCs express FLT3 and proliferate massively under the trigger of FLT3 Ligand.

References:

1.Chen, Lihua et al. Journal of inflammation research vol. 15 (2022): 5889-5904.
2.Barry, Kevin C et al. Nature medicine vol. 24,8 (2018): 1178-1191.
3.Pol, Jonathan G et al. Oncoimmunology vol. 9,1 (2020): 1755214. 
4.Durai, Vivek et al. The Journal of experimental medicine vol. 215,5 (2018): 1417-1435.